Juniper Pharmaceuticals (JNP) 10-Q 4 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 29, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	JNP
Entity Registrant Name	JUNIPER PHARMACEUTICALS INC
Entity Central Index Key	821,995
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		10,788,904

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 16,130	$ 16,762
Accounts receivable, net	6,466	5,289
Inventories	3,779	3,201
Prepaid expenses and other current assets	2,267	1,134
Total current assets	28,642	26,386
Property and equipment, net	12,917	13,041
Intangible assets, net	1,952	2,182
Goodwill	10,629	10,503
Other assets	91	96
Total assets	54,231	52,208
Liabilities and Shareholders' Equity
Accounts payable	2,997	2,873
Accrued expenses	3,987	1,918
Deferred revenue	964	914
Notes payable	249	243
Total current liabilities	8,197	5,948
Deferred revenue, net of current portion	1,215	1,553
Notes payable, net of current portion	3,203	3,289
Total liabilities	$ 12,615	$ 10,790
Commitments and contingencies
Shareholders' equity:
Preferred stock, $0.01 par value; 1,000 shares authorized Series B convertible preferred stock, 0.13 shares issued and outstanding (liquidation preference of $13)
Common stock $0.01 par value; 150,000 shares authorized; 12,202 issued and 10,791 outstanding at June 30, 2015 and 12,186 issued and 10,775 outstanding at December 31, 2014	$ 122	$ 122
Additional paid-in capital	288,634	287,660
Treasury stock, at cost (1,411 shares)	(8,579)	(8,579)
Accumulated deficit	(239,290)	(238,272)
Accumulated other comprehensive loss	179	(63)
Total shareholders' equity	41,066	40,868
Total liabilities and shareholders' equity	54,231	52,208
Series C Preferred Stock [Member]
Liabilities and Shareholders' Equity
Contingently redeemable series C preferred stock, 0.55 shares issued and outstanding (liquidation preference of $550)	$ 550	$ 550

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,202,000	12,186,000
Common stock, shares outstanding	10,791,000	10,775,000
Purchase of treasury shares	1,411,000
Series C Preferred Stock [Member]
Preferred stock, shares issued	550	550
Preferred stock, shares outstanding	550	550
Preferred stock, liquidation preference, value	$ 550	$ 550
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	130	130
Preferred stock, shares outstanding	130	130
Preferred stock, liquidation preference, value	$ 13	$ 13

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues
Product revenues	$ 6,635,000	$ 3,508,000	$ 11,510,000	$ 6,802,000
Product revenues from related party				167,000
Service revenues	2,714,000	2,110,000	5,174,000	4,588,000
Royalties	864,000	1,036,000	1,855,000	1,399,000
Royalties from related party				714,000
Total revenues	10,213,000	6,654,000	18,539,000	13,670,000
Cost of product revenues	3,521,000	1,953,000	6,633,000	4,379,000
Cost of service revenues	2,049,000	1,916,000	3,815,000	3,762,000
Total cost of revenues	5,570,000	3,869,000	10,448,000	8,141,000
Gross profit	4,643,000	2,785,000	8,091,000	5,529,000
Operating expenses
Sales and marketing	282,000	467,000	603,000	868,000
Research and development	2,132,000		3,516,000
General and administrative	2,562,000	2,239,000	5,136,000	4,690,000
Total operating expenses	4,976,000	2,706,000	9,255,000	5,558,000
(Loss) Income from operations	(333,000)	79,000	(1,164,000)	(29,000)
Interest expense, net	(27,000)	(29,000)	(54,000)	(63,000)
Change in fair value of common stock warrant liability	0	70,000		379,000
Other income	37,000	36,000	208,000	33,000
Total non-operating income	10,000	77,000	154,000	349,000
(Loss) Income before income taxes	(323,000)	156,000	(1,010,000)	320,000
Provision for income taxes	3,000	166,000	8,000	178,000
Net (loss) income	$ (326,000)	$ (10,000)	$ (1,018,000)	$ 142,000
Basic net (loss) income per common share	$ (0.03)	$ 0	$ (0.10)	$ 0.01
Diluted net loss per common share	$ (0.03)	$ (0.01)	$ (0.10)	$ (0.02)
Basic weighted average common shares outstanding	10,758	10,741	10,754	11,686
Diluted weighted average common shares outstanding	10,758	10,756	10,754	11,706

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (326)	$ (10)	$ (1,018)	$ 142
Other comprehensive income components:
Foreign currency translation	1,229	611	242	817
Total other comprehensive income	1,229	611	242	817
Comprehensive income (loss)	$ 903	$ 601	$ (776)	$ 959

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities:
Net (loss) income	$ (1,018,000)	$ 142,000
Reconciliation of net income to net cash (used in) provided by operating activities:
Depreciation and amortization	1,030,000	949,000
Change in fair value of common stock warrant liability		(379,000)
Stock-based compensation expense	904,000	346,000
Deferred income taxes		(170,000)
Changes in operating assets and liabilities:
Accounts receivable	(1,133,000)	390,000
Due from related party		900,000
Inventories	(579,000)	(966,000)
Prepaid expenses and other current assets	(981,000)	(670,000)
Other non-current assets	5,000
Accounts payable	(37,000)	282,000
Accrued expenses	2,076,000	85,000
Deferred revenue	(305,000)	(41,000)
Net cash (used in) provided by operating activities	(38,000)	868,000
Investing activities:
Purchases of property and equipment	(525,000)	(1,236,000)
Net cash used in investing activities	(525,000)	(1,236,000)
Financing activities:
Proceeds from exercise of common stock options	83,000	17,000
Purchase of treasury stock		(8,509,000)
Principal payments on notes payable	(118,000)	(121,000)
Dividends paid	(14,000)	(14,000)
Net cash used in financing activities	(49,000)	(8,627,000)
Effect of exchange rate changes on cash and cash equivalents	(20,000)	35,000
Net decrease in cash and cash equivalents	(632,000)	(8,960,000)
Cash and cash equivalents, beginning of period	16,762,000	20,715,000
Cash and cash equivalents, end of period	16,130,000	11,755,000
Supplemental cash flow information
Cash paid for interest	51,000	64,000
Cash paid for income taxes	$ 2,000	$ 3,000

Interim Consolidated Financial

Interim Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Consolidated Financial Statements	(1) Interim Consolidated Financial Statements The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Juniper Pharmaceuticals, Inc. (formerly Columbia Laboratories, Inc.) (“Juniper” or the “Company”) for the year ended December 31, 2014 filed with the SEC on March 18, 2015, (the “2014 Annual Report”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the consolidated financial information for the interim periods reported have been made. Results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the results for the year ending December 31, 2015 or any period thereafter. In April 2015, the Company changed its name from Columbia Laboratories, Inc. to Juniper Pharmaceuticals, Inc. In addition, the Company’s subsidiary formerly known as Molecular Profiles Ltd. changed its name to Juniper Pharma Services Ltd (“Juniper Pharma Services”). Revision of Prior Interim Period Financial Statements During the fourth quarter of 2014, the Company identified errors relating to the recognition of revenue for certain services transactions and contractual arrangements during 2014. Specifically, the Company determined that certain service revenues were recorded in the incorrect periods within 2014 and that revenue for certain services transactions was recognized outside the conditions required for revenue recognition under the Company’s accounting policies. The Company determined that, under U.S. GAAP rules, $0.2 million of its first quarter revenues and $0.2 million of second quarter revenues for 2014 should not have been recognized. The Company assessed the effect of the revisions, individually and in the aggregate, on its prior interim periods financial statements in accordance with the SEC’s Staff Accounting Bulletins No. 99 – Materiality and 108 – Considering the Effects of Prior Period Misstatements when Quantifying Misstatements in Current Year Financial Statements. Based on an analysis of quantitative and qualitative factors, the Company determined that its prior interim period financial statements for 2014 needed to be revised and provided such revised financial information in its 2014 Form 10-K. See Note 2 of the 2014 Form 10-K. The results for the three and six months ended June 30, 2014 incorporate the foregoing adjustments. Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; allowance for doubtful accounts; inventory reserve; impairment analysis of goodwill and intangibles including their useful lives; deferred tax assets, liabilities and valuation allowances; common stock warrant valuations; and fair value of stock options. Management evaluates its estimates on an ongoing basis. Actual results could differ from those estimates.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventories	(2) Inventories Inventories are stated at the lower of cost (first-in, first-out) or market. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands): June 30, December 31, Raw materials $ 788 $ 761 Work in process 1,903 1,095 Finished goods 1,088 1,345 Total $ 3,779 $ 3,201

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	(3) Goodwill and Intangible Assets Changes to goodwill during the six months ended June 30, 2015 were as follows (in thousands): Total Balance—December 31, 2014 $ 10,503 Effects of foreign currency translation 126 Balance—June 30, 2015 $ 10,629 Intangible assets consist of the following at June 30, 2015 and December 31, 2014 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount—June 30, 2015 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (1 ) (4 ) (4 ) (9 ) Accumulated amortization (179 ) (454 ) (316 ) (949 ) Balance—June 30, 2015 $ 120 $ 912 $ 920 $ 1,952 Trademark Developed Technology Customer Relationships Total Gross carrying amount—December 31, 2014 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (5 ) (20 ) (18 ) (43 ) Accumulated amortization (127 ) (333 ) (225 ) (685 ) Balance—December 31, 2014 $ 168 $ 1,017 $ 997 $ 2,182 Amortization expense related to the developed technology is classified as a component of cost of service revenues in the accompanying consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the accompanying consolidated statements of operations. Amortization expense for the three months ended June 30, 2015 was $0.2 million. Amortization expense for the three months ended June 30, 2014 was $0.2 million. Amortization expense for the six months ended June 30, 2015 was $0.3 million. Amortization expense for the six months ended June 30, 2014 was $0.3 million. As of June 30, 2015, amortization expense on existing intangible assets for the next five years and beyond is as follows (in thousands): Year ending December 31, Total Remainder of 2015 $ 255 2016 463 2017 367 2018 337 2019 305 2020 and thereafter 225 Total $ 1,952

Debt and other Contractual Obli

Debt and other Contractual Obligations	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt and other Contractual Obligations	(4) Debt and other Contractual Obligations In September 2013, Juniper assumed debt of $3.9 million in connection with its acquisition of Juniper Pharma Services (formerly Molecular Profiles Ltd.). Juniper Pharma Services had entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities with Lloyds TSB Bank (“Lloyds”) as administrative agent. Juniper Pharma Services had drawn down $3.9 million under the Loan Agreement and as of June 30, 2015 owed a principal balance of $3.5 million. The three loan facilities are each repayable in monthly installments: one started repayment in February 2013, and the remaining two commenced in October 2013. All facilities are due for repayment over 15 years from the date of drawdown. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95% and 2.55%, respectively. The interest rate at June 30, 2015 for these two facilities was 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The weighted average interest rate for the three loan facilities for the six months ended June 30, 2015 was 3.00%. The Loan Agreement is secured by the mortgaged property and an unlimited lien on other assets of Juniper Pharma Services. The Loan Agreement contains financial covenants that limit the amount of indebtedness Juniper Pharma Services may incur, requires Juniper Pharma Services to maintain certain levels of net worth, and restricts Juniper Pharma Service’s ability to materially alter the character of its business. As of June 30, 2015, Juniper Pharma Services is in compliance with all of the covenants under the Loan Agreement. In September 2013, Juniper assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Juniper Pharma Services used this grant to fund the expansion of its facility. As part of the arrangement, Juniper Pharma Services is required to create and maintain certain full-time equivalent personnel levels through October 2017. As of June 30, 2015, the Company is in compliance with the covenants of the arrangement. The Regional Growth Fund obligation is recognized in the other income line item in the consolidated statement of operations and is recognized on a decelerated basis over the obligation period through October 2017. As of June 30, 2015, the obligation is valued at $1.9 million and is recorded as deferred revenue on the consolidated balance sheets. The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands): Year Total Remainder of 2015 $ 314 2016 817 2017 755 Total $ 1,886

Intra-Vaginal Ring Technology L

Intra-Vaginal Ring Technology Licensing	6 Months Ended
	Jun. 30, 2015
Text Block [Abstract]
Intra-Vaginal Ring Technology Licensing	(5) Intra-Vaginal Ring Technology Licensing In March 2015, the Company licensed exclusive worldwide rights (“License Agreement”) to a proprietary intra-vaginal ring (“IVR”) technology. Due to its novel polymer composition and segmentation capability, the IVR has the ability to deliver drugs, including larger molecules such as peptides, at different dosages and release rates within a single segmented ring. This technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology (“MIT”) and Dr. William Crowley from Massachusetts General Hospital (“MGH”) and Harvard Medical School. Drs. Langer and Crowley have each agreed to serve a three-year term as strategic advisors to the Company in exchange for an upfront one-time payment plus quarterly fees and equity compensation. Juniper has agreed to incur minimum annual expenditures to develop products using the IVR technology, and will make milestone-based payments to MGH/MIT (the “Licensor”) when various stages of product development and commercialization are achieved. The Company will also share a portion of any royalties or sublicense revenues received from products utilizing the IVR technology with MGH and MIT. Juniper has the right to terminate the License Agreement by giving 90 days advance written notice to the Licensor. The Licensor has the right to terminate the License Agreement should Juniper fail to make payments due under the License Agreement, subject to a 15 day cure period, or fail to maintain the insurance required by the license Agreement. The Licensor may also terminate the License Agreement based on Juniper’s non-financial default under the License Agreement, subject to a 60 day cure period.

Segments and Geographic Informa

Segments and Geographic Information	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segments and Geographic Information	(6) Segments and Geographic Information The Company currently operates in two segments: product and service. The product segment oversees the supply chain and manufacturing of CRINONE ® The Company’s largest customer, Merck Serono, acquires product from the Company through its Switzerland-based subsidiary, which it then sells throughout the world excluding the U.S. The Company’s primary domestic customer, Allergan, is responsible for the commercialization and sale of progesterone products in the United States. Juniper Pharma Services provides services to customers in many jurisdictions; including the European Union, United States, Australia and Canada. The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended Six Months Ended 2015 2014 2015 2014 United States $ 1,877 $ 2,144 $ 3,624 $ 4,645 Switzerland 6,691 3,522 11,629 7,053 Other countries 1,645 988 3,286 1,972 Total $ 10,213 $ 6,654 $ 18,539 $ 13,670 Total assets: June 30, December 31, United States $ 18,675 $ 18,212 United Kingdom 32,457 32,140 Other countries 3,099 1,856 Total $ 54,231 $ 52,208 Long-lived assets: June 30, December 31, United Kingdom $ 11,993 $ 12,361 Other countries 1,015 776 Total $ 13,008 $ 13,137 No other individual country represented greater than 10% of total revenues, total assets, or total long-lived assets for any period presented. For the three months ended June 30, 2015 and 2014, Merck Serono and Allergan accounted for 65% and 8%, and 53% and 15% of total revenues, respectively. For the six months ended June 30, 2015 and 2014, Merck Serono and Allergan accounted for 62% and 10%, and 47% and 15% of total revenues, respectively. For the three months ended June 30, 2015 one customer accounted for 10% of total service revenues. No additional customers accounted for 10% or more of total revenues for the three or six months ended June 30, 2015 and 2014. At June 30, 2015 Merck Serono and Allergan made up 67% and 33% of the product segment accounts receivable, respectively. At December 31, 2014 Merck Serono and Allergan accounted for 54% and 46% of the product segment accounts receivable, respectively. At June 30, 2015 one customer accounted for 11% of total service segment net accounts receivable. No other customers accounted for greater than 10% of the service segment accounts receivable. At December 31, 2014 two customers accounted for 18% and 11% of total service segment accounts receivable. The following summarizes other information by segment for the three months ended June 30, 2015 (in thousands): Product Service Total Revenues Product revenues $ 6,635 $ — $ 6,635 Service revenues — 2,714 2,714 Royalties 864 — 864 Total revenues 7,499 2,714 10,213 Cost of product revenues 3,521 — 3,521 Cost of service revenues — 2,049 2,049 Total cost of revenues 3,521 2,049 5,570 Gross profit 3,978 665 4,643 Total operating expenses 4,976 Total non-operating income 10 Loss before income taxes (323 ) The following summarizes other information by segment for the three months ended June 30, 2014 (in thousands): Product Service Total Revenues Product revenues $ 3,508 $ — $ 3,508 Service revenues — 2,110 2,110 Royalties 1,036 — 1,036 Other revenues — — — Total revenues 4,544 2,110 6,654 Cost of product revenues 1,953 — 1,953 Cost of service revenues — 1,916 1,916 Total cost of revenues 1,953 1,916 3,869 Gross profit 2,591 194 2,785 Total operating expenses 2,706 Total non-operating income 77 Income before income taxes 156 The following summarizes other information by segment for the six months ended June 30, 2015 (in thousands): Product Service Total Revenues Product revenues $ 11,510 $ — $ 11,510 Service revenues — 5,174 5,174 Royalties 1,855 — 1,855 Total revenues 13,365 5,174 18,539 Cost of product revenues 6,633 — 6,633 Cost of service revenues — 3,815 3,815 Total cost of revenues 6,633 3,815 10,448 Gross profit 6,732 1,359 8,091 Total operating expenses 9,255 Total non-operating income 154 Loss before income taxes (1,010 ) The following summarizes other information by segment for the six months ended June 30, 2014 (in thousands): Product Service Total Revenues Product revenues $ 6,969 $ — $ 6,969 Service revenues — 4,588 4,588 Royalties 2,113 — 2,113 Other revenues — — — Total revenues 9,082 4,588 13,670 Cost of product revenues 4,379 — 4,379 Cost of service revenues — 3,762 3,762 Total cost of revenues 4,379 3,762 8,141 Gross profit 4,703 826 5,529 Total operating expenses 5,558 Total non-operating income 349 Income before income taxes 320

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	(7) Property and Equipment Property and equipment consists of the following (in thousands): Estimated June 30, 2015 December 31, 2014 Machinery and equipment 3-10 $ 6,425 $ 6,080 Furniture and fixtures 3-5 1,035 1,019 Computer equipment and software 3 447 188 Buildings Up to 39 9,170 9,062 Land Indefinite 597 590 Construction in-process 61 107 17,735 17,046 Less: Accumulated depreciation (4,818 ) (4,005 ) Total $ 12,917 $ 13,041 Depreciation expense was $0.4 million for both the three months ended June 30, 2015 and 2014. Depreciation expense for the six months ended June 30, 2015 and 2014 was $0.8 million and $0.7 million, respectively.

Net (Loss) Income Per Common Sh

Net (Loss) Income Per Common Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net (Loss) Income Per Common Share	(8) Net (Loss) Income Per Common Share The calculation of basic and diluted (loss) per common and common equivalent share is as follows (in thousands except for per share data): Three Months Ended Six Months Ended 2015 2014 2015 2014 Basic (loss) income per common share Net (loss) income $ (326 ) $ (10 ) $ (1,018 ) $ 142 Less: Preferred stock dividends (7 ) (7 ) (14 ) (14 ) Net (loss) income applicable to common stock $ (333 ) $ (17 ) $ (1,032 ) $ 128 Basic weighted average number of common shares outstanding 10,758 10,741 10,754 11,686 Basic net (loss) income per common share $ (0.03 ) $ (0.00 ) $ (0.10 ) $ 0.01 Diluted (loss) income per common share Net (loss) income applicable to common stock $ (333 ) $ (17 ) $ (1,032 ) $ 128 Add: Preferred stock dividends — 7 — 14 Less: Fair value of stock warrants for dilutive warrants — (70 ) — (379 ) Net (loss) applicable to dilutive common stock $ (333 ) $ (80 ) $ (1,032 ) $ (237 ) Basic weighted average number of common shares outstanding 10,758 10,741 10,754 11,686 Effect of dilutive securities Dilutive stock awards — — — — Dilutive preferred share conversions — 15 — 20 — 15 — 20 Diluted weighted average number of common shares outstanding 10,758 10,756 10,754 11,706 Diluted net (loss) per common share $ (0.03 ) $ (0.01 ) $ (0.10 ) $ (0.02 ) Basic (loss) income per common share is computed by dividing the net income, less preferred dividends, by the weighted-average number of shares of common stock outstanding during a period. The diluted loss per common share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period. Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive. Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1.5 million and 1.8 million in each of the three month periods ended June 30, 2015 and 2014, respectively, because the awards were anti-dilutive. Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1.5 million and 1.8 million in each of the six month periods ended June 30, 2015 and 2014, respectively, because the awards were anti-dilutive.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Accumulated Other Comprehensive Loss	(9) Accumulated Other Comprehensive Loss Changes to accumulated other comprehensive income during the six months ended June 30, 2015 were as follows (in thousands): Foreign Currency Accumulated Other Balance—December 31, 2014 $ (63 ) $ (63 ) Current period other comprehensive income 242 242 Balance—June 30, 2015 $ 179 $ 179

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(10) Stock-Based Compensation Stock-based compensation expense for the three months ended June 30, 2015 and 2014 was $0.4 million and $0.2 million, respectively. Stock-based compensation expense for the six months ended June 30, 2015 and 2014 was $0.9 million and $0.3 million, respectively. Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 Cost of revenues $ 22 $ 13 $ 41 $ 13 Sales and marketing 10 13 18 16 Research and development 233 — 608 — General and administrative 107 156 237 317 Total $ 372 $ 182 $ 904 $ 346 Cash received for option exercises was $0.1 million and $17,000 for the six months ended June 30, 2015 and 2014, respectively. Juniper granted 232,000 and 222,000 stock options to employees during the six months ended June 30, 2015 and 2014, respectively. The Company records stock-based compensation expense for stock options granted to non-employees based on the fair value of the stock options, which is re-measured over the graded vesting term resulting in periodic adjustments to stock-based compensation expense. In March 2015, 240,000 stock options were granted by the Company to non-employees. One-third of the options vested immediately resulting in $0.4 million of stock based compensation expense. During the three months ended June 30, 2015 the Company has recorded stock based compensation expense of $0.2 million. The stock based compensation expense recorded for non-employees is reflected in the research and development line of the statement of operations. The remaining options will be re-measured over a 1.75 year period from the date of grant. The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock-based awards. The weighted-average grant date fair values of the options granted during the six months ended June 30, 2015 and 2014 were $3.62 and $4.51, respectively for employees and $4.44 and $0 for non-employees, using the following assumptions: Six Months Ended 2015 2014 Risk free interest rate 0.87% - 1.47%* 1.64 % Expected term 4.56 - 7 years* 4.75 years Dividend yield — — Expected volatility 76.76% - 82.88%* 81.36 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Juniper’s estimated expected stock price volatility is based on its own historical volatility. Juniper’s expected term of options granted during the six months ended June 30, 2015 and 2014 was derived using the simplified method for employees and the contractual term of the option for non-employees. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. * Represents the fair value assumptions for the non-employee options. As of June 30, 2015, the total unrecognized compensation cost related to outstanding stock options and restricted stock awards expected to vest was $2.4 million, which the Company expects to recognize over a weighted-average period of 2.81 years.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(11) Fair Value of Financial Instruments U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: Level 1: Quoted prices in active markets for identical assets and liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The fair value of cash and cash equivalents are classified as Level 1 at June 30, 2015 and December 31, 2014. The fair value of the common stock warrant liability was $0 as of March 31, 2015 and the warrant expired in April 2015. Therefore, during the three months ended June 30, 2015 no income or expense was recorded to adjust the value of the common stock warrant liability to fair value. The value of the common stock warrant liability was determined by using the Black-Scholes option pricing model, which is based on the Company’s stock price at measurement date, exercise price of the common stock warrants, risk-free interest rate and historical volatility, and are classified as a Level 2 measurement. During the three and six months ended June 30, 2014 the Company recorded income of $0.1 million and $0.4 million, respectively, to adjust the value of the common stock warrant liability to fair value. The fair values of accounts receivable and accounts payable approximate their respective carrying amounts. The Company’s long-term debt is carried at amortized face value, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	(12) Related Party Transactions On March 7, 2014 the Company acquired all of its common stock beneficially owned by Allergan, which represented approximately 11.5% of the Company’s outstanding common stock at that time. Immediately following the closing of the stock repurchase and as of June 30, 2015, Allergan did not own any of the Company’s outstanding common stock. Juniper purchased the 1.4 million shares held by Allergan at a price of $6.08 per share, which represented a 10.75% discount to the market closing price on March 6, 2014. The total purchase price was approximately $8.5 million. Pursuant to its Purchase and Collaboration Agreement with Allergan, Juniper receives royalties equal to a minimum of 10% of annual net sales of CRINONE by Allergan for annual net sales up to $150 million; 15% for sales above $150 million but less than $250 million; and 20% for annual net sales of $250 million and over. Allergan also purchased the remaining raw materials Juniper had on hand in the six months ended June 30, 2014. The table below presents the transactions between the Company and Allergan during the six months ended June 30, 2014 (prior to the time Allergan ceased to be a related party) (in thousands): Six Months Revenues Net product revenues $ 167 Royalties 714 Total net revenues $ 881 As of June 30, 2015 and December 31, 2014 any amounts due from Allergan are now classified as a component of accounts receivable, net on the consolidated balance sheet. There were no amounts due to Allergan at June 30, 2015 and December 31, 2014.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes During the three months ended June 30, 2015 and 2014, Juniper recorded income tax expense of $3,000 and $0.2 million, respectively, representing an effective tax rate of 0.9% and 106%, respectively. During the six months ended June 30, 2015 and 2014, Juniper recorded income tax expense of $8,000 and $0.2 million, respectively, representing an effective tax rate of 0.8% and 51%, respectively. The income tax provision for the three and six months ended June 30, 2015 is primarily attributable to state taxes owed. The income tax provision for the three and six months ended June 30, 2014 is primarily attributable to a one-time clawback provision under a New Jersey Economic Development Authority program relating to the sale of the Company’s state net operating losses, offset partially by a benefit recorded due to taxable losses generated in foreign jurisdictions. Juniper files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Juniper is no longer subject to U.S. federal income tax examinations by tax authorities for years prior to 2012. Additionally, with few exceptions, Juniper is no longer subject to U.S. state tax examinations for years prior to 2012.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	(14) Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts.” The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2018 and, at that time the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is not permitted. The Company is currently evaluating the method and impact that the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern.

Interim Consolidated Financia21

Interim Consolidated Financial Statements (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Revision of Prior Interim Period Financial Statements	Revision of Prior Interim Period Financial Statements During the fourth quarter of 2014, the Company identified errors relating to the recognition of revenue for certain services transactions and contractual arrangements during 2014. Specifically, the Company determined that certain service revenues were recorded in the incorrect periods within 2014 and that revenue for certain services transactions was recognized outside the conditions required for revenue recognition under the Company’s accounting policies. The Company determined that, under U.S. GAAP rules, $0.2 million of its first quarter revenues and $0.2 million of second quarter revenues for 2014 should not have been recognized. The Company assessed the effect of the revisions, individually and in the aggregate, on its prior interim periods financial statements in accordance with the SEC’s Staff Accounting Bulletins No. 99 – Materiality and 108 – Considering the Effects of Prior Period Misstatements when Quantifying Misstatements in Current Year Financial Statements. Based on an analysis of quantitative and qualitative factors, the Company determined that its prior interim period financial statements for 2014 needed to be revised and provided such revised financial information in its 2014 Form 10-K. See Note 2 of the 2014 Form 10-K. The results for the three and six months ended June 30, 2014 incorporate the foregoing adjustments.
Management Estimates	Management Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; allowance for doubtful accounts; inventory reserve; impairment analysis of goodwill and intangibles including their useful lives; deferred tax assets, liabilities and valuation allowances; common stock warrant valuations; and fair value of stock options. Management evaluates its estimates on an ongoing basis. Actual results could differ from those estimates.
Recent Accounting Pronouncements	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which provides guidance for revenue recognition. ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets and supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition,” and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts.” The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the Company beginning January 1, 2018 and, at that time the Company may adopt the new standard under the full retrospective approach or the modified retrospective approach. Early adoption is not permitted. The Company is currently evaluating the method and impact that the adoption of ASU 2014-09 will have on the Company’s consolidated financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following (in thousands): June 30, December 31, Raw materials $ 788 $ 761 Work in process 1,903 1,095 Finished goods 1,088 1,345 Total $ 3,779 $ 3,201

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes to Goodwill	Changes to goodwill during the six months ended June 30, 2015 were as follows (in thousands): Total Balance—December 31, 2014 $ 10,503 Effects of foreign currency translation 126 Balance—June 30, 2015 $ 10,629
Changes to Intangible Assets	Intangible assets consist of the following at June 30, 2015 and December 31, 2014 (in thousands): Trademark Developed Technology Customer Relationships Total Gross carrying amount—June 30, 2015 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (1 ) (4 ) (4 ) (9 ) Accumulated amortization (179 ) (454 ) (316 ) (949 ) Balance—June 30, 2015 $ 120 $ 912 $ 920 $ 1,952 Trademark Developed Technology Customer Relationships Total Gross carrying amount—December 31, 2014 $ 300 $ 1,370 $ 1,240 $ 2,910 Foreign currency translation adjustment (5 ) (20 ) (18 ) (43 ) Accumulated amortization (127 ) (333 ) (225 ) (685 ) Balance—December 31, 2014 $ 168 $ 1,017 $ 997 $ 2,182
Amortization Expense on Existing Intangible Assets for Next Five Years and Beyond	As of June 30, 2015, amortization expense on existing intangible assets for the next five years and beyond is as follows (in thousands): Year ending December 31, Total Remainder of 2015 $ 255 2016 463 2017 367 2018 337 2019 305 2020 and thereafter 225 Total $ 1,952

Debt and other Contractual Ob24

Debt and other Contractual Obligations (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Summary of Other Income on Obligation	The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands): Year Total Remainder of 2015 $ 314 2016 817 2017 755 Total $ 1,886

Segments and Geographic Infor25

Segments and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Selected Information by Geographic Area	The following tables show selected information by geographic area (in thousands): Revenues: Three Months Ended Six Months Ended 2015 2014 2015 2014 United States $ 1,877 $ 2,144 $ 3,624 $ 4,645 Switzerland 6,691 3,522 11,629 7,053 Other countries 1,645 988 3,286 1,972 Total $ 10,213 $ 6,654 $ 18,539 $ 13,670 Total assets: June 30, December 31, United States $ 18,675 $ 18,212 United Kingdom 32,457 32,140 Other countries 3,099 1,856 Total $ 54,231 $ 52,208 Long-lived assets: June 30, December 31, United Kingdom $ 11,993 $ 12,361 Other countries 1,015 776 Total $ 13,008 $ 13,137
Schedule of Other Information by Segment	The following summarizes other information by segment for the three months ended June 30, 2015 (in thousands): Product Service Total Revenues Product revenues $ 6,635 $ — $ 6,635 Service revenues — 2,714 2,714 Royalties 864 — 864 Total revenues 7,499 2,714 10,213 Cost of product revenues 3,521 — 3,521 Cost of service revenues — 2,049 2,049 Total cost of revenues 3,521 2,049 5,570 Gross profit 3,978 665 4,643 Total operating expenses 4,976 Total non-operating income 10 Loss before income taxes (323 ) The following summarizes other information by segment for the three months ended June 30, 2014 (in thousands): Product Service Total Revenues Product revenues $ 3,508 $ — $ 3,508 Service revenues — 2,110 2,110 Royalties 1,036 — 1,036 Other revenues — — — Total revenues 4,544 2,110 6,654 Cost of product revenues 1,953 — 1,953 Cost of service revenues — 1,916 1,916 Total cost of revenues 1,953 1,916 3,869 Gross profit 2,591 194 2,785 Total operating expenses 2,706 Total non-operating income 77 Income before income taxes 156 The following summarizes other information by segment for the six months ended June 30, 2015 (in thousands): Product Service Total Revenues Product revenues $ 11,510 $ — $ 11,510 Service revenues — 5,174 5,174 Royalties 1,855 — 1,855 Total revenues 13,365 5,174 18,539 Cost of product revenues 6,633 — 6,633 Cost of service revenues — 3,815 3,815 Total cost of revenues 6,633 3,815 10,448 Gross profit 6,732 1,359 8,091 Total operating expenses 9,255 Total non-operating income 154 Loss before income taxes (1,010 ) The following summarizes other information by segment for the six months ended June 30, 2014 (in thousands): Product Service Total Revenues Product revenues $ 6,969 $ — $ 6,969 Service revenues — 4,588 4,588 Royalties 2,113 — 2,113 Other revenues — — — Total revenues 9,082 4,588 13,670 Cost of product revenues 4,379 — 4,379 Cost of service revenues — 3,762 3,762 Total cost of revenues 4,379 3,762 8,141 Gross profit 4,703 826 5,529 Total operating expenses 5,558 Total non-operating income 349 Income before income taxes 320

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (in thousands): Estimated June 30, 2015 December 31, 2014 Machinery and equipment 3-10 $ 6,425 $ 6,080 Furniture and fixtures 3-5 1,035 1,019 Computer equipment and software 3 447 188 Buildings Up to 39 9,170 9,062 Land Indefinite 597 590 Construction in-process 61 107 17,735 17,046 Less: Accumulated depreciation (4,818 ) (4,005 ) Total $ 12,917 $ 13,041

Net (Loss) Income Per Common 27

Net (Loss) Income Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Calculation of Basic and Diluted (Loss) Income Per Common and Common Equivalent Share	The calculation of basic and diluted (loss) per common and common equivalent share is as follows (in thousands except for per share data): Three Months Ended Six Months Ended 2015 2014 2015 2014 Basic (loss) income per common share Net (loss) income $ (326 ) $ (10 ) $ (1,018 ) $ 142 Less: Preferred stock dividends (7 ) (7 ) (14 ) (14 ) Net (loss) income applicable to common stock $ (333 ) $ (17 ) $ (1,032 ) $ 128 Basic weighted average number of common shares outstanding 10,758 10,741 10,754 11,686 Basic net (loss) income per common share $ (0.03 ) $ (0.00 ) $ (0.10 ) $ 0.01 Diluted (loss) income per common share Net (loss) income applicable to common stock $ (333 ) $ (17 ) $ (1,032 ) $ 128 Add: Preferred stock dividends — 7 — 14 Less: Fair value of stock warrants for dilutive warrants — (70 ) — (379 ) Net (loss) applicable to dilutive common stock $ (333 ) $ (80 ) $ (1,032 ) $ (237 ) Basic weighted average number of common shares outstanding 10,758 10,741 10,754 11,686 Effect of dilutive securities Dilutive stock awards — — — — Dilutive preferred share conversions — 15 — 20 — 15 — 20 Diluted weighted average number of common shares outstanding 10,758 10,756 10,754 11,706 Diluted net (loss) per common share $ (0.03 ) $ (0.01 ) $ (0.10 ) $ (0.02 )

Accumulated Other Comprehensi28

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	Changes to accumulated other comprehensive income during the six months ended June 30, 2015 were as follows (in thousands): Foreign Currency Accumulated Other Balance—December 31, 2014 $ (63 ) $ (63 ) Current period other comprehensive income 242 242 Balance—June 30, 2015 $ 179 $ 179

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense Allocation	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands): Three Months Ended Six Months Ended 2015 2014 2015 2014 Cost of revenues $ 22 $ 13 $ 41 $ 13 Sales and marketing 10 13 18 16 Research and development 233 — 608 — General and administrative 107 156 237 317 Total $ 372 $ 182 $ 904 $ 346
Assumptions Used to Weighted-Average Grant Date Fair Values of Options Granted	The weighted-average grant date fair values of the options granted during the six months ended June 30, 2015 and 2014 were $3.62 and $4.51, respectively for employees and $4.44 and $0 for non-employees, using the following assumptions: Six Months Ended 2015 2014 Risk free interest rate 0.87% - 1.47%* 1.64 % Expected term 4.56 - 7 years* 4.75 years Dividend yield — — Expected volatility 76.76% - 82.88%* 81.36 % * Represents the fair value assumptions for the non-employee options.

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The table below presents the transactions between the Company and Allergan during the six months ended June 30, 2014 (prior to the time Allergan ceased to be a related party) (in thousands): Six Months Revenues Net product revenues $ 167 Royalties 714 Total net revenues $ 881

Interim Consolidated Financia31

Interim Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue	$ 10,213	$ 6,654		$ 18,539	$ 13,670
Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue		$ 200	$ 200

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Inventory, Net, Items Net of Reserve Alternative [Abstract]
Raw materials	$ 788	$ 761
Work in process	1,903	1,095
Finished goods	1,088	1,345
Total	$ 3,779	$ 3,201

Goodwill and Intangible Asset33

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 10,503
Effects of foreign currency translation	126
Ending balance	$ 10,629

Goodwill and Intangible Asset34

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,910	$ 2,910
Foreign currency translation adjustment	(9)	(43)
Accumulated amortization	(949)	(685)
Balance	1,952	2,182
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	300	300
Foreign currency translation adjustment	(1)	(5)
Accumulated amortization	(179)	(127)
Balance	120	168
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,370	1,370
Foreign currency translation adjustment	(4)	(20)
Accumulated amortization	(454)	(333)
Balance	912	1,017
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,240	1,240
Foreign currency translation adjustment	(4)	(18)
Accumulated amortization	(316)	(225)
Balance	$ 920	$ 997

Goodwill and Intangible Asset35

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Intangible Liability Disclosure [Abstract]
Amortization expense	$ 0.2	$ 0.2	$ 0.3	$ 0.3

Goodwill and Intangible Asset36

Goodwill and Intangible Assets - Amortization Expense on Existing Intangible Assets for Next Five Years and Beyond (Detail) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2015	$ 255
2,016	463
2,017	367
2,018	337
2,019	305
2020 and thereafter	225
Total	$ 1,952	$ 2,182

Debt and Other Contractual Ob37

Debt and Other Contractual Obligations - Additional Information (Detail) - Juniper Pharma Services [Member] $ in Millions	1 Months Ended	6 Months Ended
	Sep. 30, 2013USD ($)	Jun. 30, 2015USD ($)Facilities
Debt Instrument [Line Items]
Debt assumed	$ 3.9
Number of loan facilities | Facilities		3
Withdrawn amount		$ 3.9
Owes due to foreign currency revaluation		$ 3.5
Weighted average interest rate for the period		3.00%
Loan facilities repayment period		15 years
Business acquisition maturity period		2017-10
Regional Growth Fund [Member]
Debt Instrument [Line Items]
Debt assumed	$ 2.5
Deferred revenue		$ 1.9
Loan Facility One [Member]
Debt Instrument [Line Items]
Loan repayment commencement period		2013-02
Interest rate at the end of period		2.45%
Loan facilities bear interest rate		1.95%
Loan facility interest rate description		Base rate plus 1.95%
Loan Facility Two [Member]
Debt Instrument [Line Items]
Loan repayment commencement period		2013-10
Interest rate at the end of period		3.05%
Loan facilities bear interest rate		2.55%
Loan facility interest rate description		Base rate plus 2.55%
Loan Facility Three [Member]
Debt Instrument [Line Items]
Loan repayment commencement period		2013-10
Loan facilities bear interest rate		3.52%

Debt and Other Contractual Ob38

Debt and Other Contractual Obligations - Summary of Other Income on Obligation (Detail) - Regional Growth Fund [Member] - Juniper Pharma Services [Member] $ in Thousands	Jun. 30, 2015USD ($)
Contractual Obligation [Line Items]
Remainder of 2015	$ 314
2,016	817
2,017	755
Total	$ 1,886

Intra-Vaginal Ring Technology39

Intra-Vaginal Ring Technology Licensing - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2015
License Agreements [Line Items]
License agreement notice period	90 days
Financial Default [Member]
License Agreements [Line Items]
Cure period	15 days
Non Financial Default [Member]
License Agreements [Line Items]
Cure period	60 days

Segments and Geographic Infor40

Segments and Geographic Information - Additional Information (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015LocationCustomer	Jun. 30, 2014Customer	Jun. 30, 2015LocationCustomerSegmentCountry	Jun. 30, 2014Customer	Dec. 31, 2014Customer
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | Segment			2
Number of operational location | Location	1		1
Number of countries represented greater than 10% of total revenues | Country			0
Number of countries represented greater than 10% of total assets | Country			0
Number of countries represented greater than 10% of total long-lived assets | Country			0
Number of customers			1		2
Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of customer accounted for 10% of total service revenues	1
Additional customers accounted for 10% or more of total revenues	0	0	0	0
Accounts Receivable [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Additional customers accounted for 10% or more of total revenues			0
Accounts Receivable [Member] | Customer One [Member] | Service [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Additional customers accounted for 10% or more of total revenues			1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Merck Serono [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Accounts receivable	65.00%	8.00%	62.00%	10.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Allergan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Accounts receivable	53.00%	15.00%	47.00%	15.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Merck Serono [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Accounts receivable			67.00%		54.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Allergan [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Accounts receivable			33.00%		46.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Accounts receivable			11.00%		18.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Accounts receivable					11.00%

Segments and Geographic Infor41

Segments and Geographic Information - Selected Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 10,213	$ 6,654	$ 18,539	$ 13,670
Total Assets	54,231		54,231		$ 52,208
Total Long-lived Assets	13,008		13,008		13,137
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	1,877	2,144	3,624	4,645
Total Assets	18,675		18,675		18,212
Switzerland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	6,691	3,522	11,629	7,053
United Kingdom [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	32,457		32,457		32,140
Total Long-lived Assets	11,993		11,993		12,361
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	1,645	$ 988	3,286	$ 1,972
Total Assets	3,099		3,099		1,856
Total Long-lived Assets	$ 1,015		$ 1,015		$ 776

Segments and Geographic Infor42

Segments and Geographic Information - Schedule of Other Information by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues
Product revenues	$ 6,635	$ 3,508	$ 11,510	$ 6,802
Service revenues	2,714	2,110	5,174	4,588
Royalties	864	1,036	1,855	1,399
Other revenues		0		0
Total revenues	10,213	6,654	18,539	13,670
Cost of product revenues	3,521	1,953	6,633	4,379
Cost of service revenues	2,049	1,916	3,815	3,762
Total cost of revenues	5,570	3,869	10,448	8,141
Gross profit	4,643	2,785	8,091	5,529
Total operating expenses	4,976	2,706	9,255	5,558
Total non-operating income	10	77	154	349
Income (loss) before income taxes	(323)	156	(1,010)	320
Product [Member]
Revenues
Product revenues	6,635	3,508	11,510	6,969
Royalties	864	1,036	1,855	2,113
Other revenues		0		0
Total revenues	7,499	4,544	13,365	9,082
Cost of product revenues	3,521	1,953	6,633	4,379
Total cost of revenues	3,521	1,953	6,633	4,379
Gross profit	3,978	2,591	6,732	4,703
Service [Member]
Revenues
Service revenues	2,714	2,110	5,174	4,588
Other revenues		0		0
Total revenues	2,714	2,110	5,174	4,588
Cost of service revenues	2,049	1,916	3,815	3,762
Total cost of revenues	2,049	1,916	3,815	3,762
Gross profit	$ 665	$ 194	$ 1,359	$ 826

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 17,735	$ 17,046
Less: Accumulated depreciation	(4,818)	(4,005)
Total	12,917	13,041
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 6,425	6,080
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 1,035	1,019
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	3 years
Property plant and equipment, gross	$ 447	188
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 9,170	9,062
Buildings [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	39 years
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment useful life (in years)	Indefinite
Property plant and equipment, gross	$ 597	590
Construction in-Process [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 61	$ 107

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Depreciation [Abstract]
Depreciation expense	$ 0.4	$ 0.4	$ 0.8	$ 0.7

Net (Loss) Income Per Common 45

Net (Loss) Income Per Common Share - Calculation of Basic and Diluted (Loss) Income Per Common and Common Equivalent Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Basic (loss) income per common share
Net (loss) income	$ (326)	$ (10)	$ (1,018)	$ 142
Less: Preferred stock dividends	(7)	(7)	(14)	(14)
Net (loss) income applicable to common stock	$ (333)	$ (17)	$ (1,032)	$ 128
Basic weighted average number of common shares outstanding	10,758	10,741	10,754	11,686
Basic net (loss) income per common share	$ (0.03)	$ 0	$ (0.10)	$ 0.01
Diluted (loss) income per common share
Net (loss) income applicable to common stock	$ (333)	$ (17)	$ (1,032)	$ 128
Add: Preferred stock dividends		7		14
Less: Fair value of stock warrants for dilutive warrants		(70)		(379)
Net (loss) applicable to dilutive common stock	$ (333)	$ (80)	$ (1,032)	$ (237)
Basic weighted average number of common shares outstanding	10,758	10,741	10,754	11,686
Effect of dilutive securities
Dilutive stock awards	0	0	0	0
Dilutive preferred share conversions		15		20
Weighted average number of diluted shares outstanding adjustment		15		20
Diluted weighted average number of common shares outstanding	10,758	10,756	10,754	11,706
Diluted net (loss) per common share	$ (0.03)	$ (0.01)	$ (0.10)	$ (0.02)

Net (Loss) Income Per Common 46

Net (Loss) Income Per Common Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	1.5	1.8	1.5	1.8

Accumulated Other Comprehensi47

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance - December 31, 2014			$ (63)
Current period other comprehensive income	$ 1,229	$ 611	242	$ 817
Balance - June 30, 2015	179		179
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance - December 31, 2014			(63)
Current period other comprehensive income			242
Balance - June 30, 2015	$ 179		$ 179

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation		$ 400	$ 200	$ 904	$ 346
Cash received for option exercised				$ 83	$ 17
Company options granted to employees, in shares				232,000	222,000
Stock based compensation expense		372	$ 182	$ 904	$ 346
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized		2,400		$ 2,400
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition				2 years 9 months 22 days
Non Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Company options granted to employees, in shares	240,000
Stock based compensation expense	$ 400	$ 200
Options vested	3333.00%
Options re-measurement period				1 year 9 months
Weighted-average grand date fair values of options granted to non employees				$ 4.44	$ 0
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grand date fair values of options granted to non employees				$ 3.62	$ 4.51

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Allocation (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 372	$ 182	$ 904	$ 346
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	22	13	41	13
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	10	13	18	16
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	233		608
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 107	$ 156	$ 237	$ 317

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used to Weighted-Average Grant Date Fair Values of Options Granted (Detail)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Schedule Of Net Revenue Attributable To Medicaid Medicare Insurance And Self Pay As Percentage Of Net Air Medical Revenues [Line Items]
Risk free interest rate		1.64%
Expected term		4 years 9 months
Dividend yield		0.00%
Expected volatility		81.36%
Minimum [Member]
Schedule Of Net Revenue Attributable To Medicaid Medicare Insurance And Self Pay As Percentage Of Net Air Medical Revenues [Line Items]
Risk free interest rate	0.87%
Expected term	4 years 6 months 22 days
Dividend yield	0.00%
Expected volatility	76.76%
Maximum [Member]
Schedule Of Net Revenue Attributable To Medicaid Medicare Insurance And Self Pay As Percentage Of Net Air Medical Revenues [Line Items]
Risk free interest rate	1.47%
Expected term	7 years
Dividend yield	0.00%
Expected volatility	82.88%

Fair Value of Financial Instr51

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015
Debt Instrument Fair Value Carrying Value [Abstract]
Expense (income) recognized on adjustment of fair value of stock warrant liability	$ 0	$ (70,000)		$ (379,000)
Derivative liability, fair value, gross liability					$ 0
Warrant expiry period			Apr. 30, 2015

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Allergan [Member] - USD ($) $ / shares in Units, shares in Millions	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Mar. 07, 2014
Related Party Transaction [Line Items]
Percentage of ownership of outstanding common stock			11.50%
Number of shares repurchased	1.4
Number of shares repurchased price per share	$ 6.08
Percentage of closing price discount on share repurchase	10.75%
Purchase price	$ 8,500,000
Amounts due to related parties	$ 0	$ 0
CRINONE Royalties [Member]
Related Party Transaction [Line Items]
Percentage of royalties received	10.00%
Annual net sales	15.00%
Percentage of royalties received for sales between range	20.00%
Condition one for royalties received	$ 150,000,000
Condition two for royalties received	$ 250,000,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2014USD ($)
Related Party Transaction [Line Items]
Net product revenues	$ 167
Royalties	714
Allergan [Member]
Related Party Transaction [Line Items]
Net product revenues	167
Royalties	714
Total net revenues	$ 881

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income tax expense	$ 3	$ 166	$ 8	$ 178
Effective tax rate	0.90%	106.00%	0.80%	51.00%